Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal CancerLeonard B. Saltz, Langdon L. Miller, John V. Cox et al.|New England Journal of Medicine|2000Cited by 3k
Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing <i>KIT</i>Charles D. Blanke, Heikki Joensuu|Journal of Clinical Oncology|2008Cited by 1k
Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With <i>KRAS</i> Wild-Type Advanced or Metastatic Colorectal CancerAlan P. Venook, Charles D. Blanke, Robert J. Mayer et al.|JAMA|2017Cited by 891
NCCN Task Force Report: Management of Patients with Gastrointestinal Stromal Tumor (GIST)—Update of the NCCN Clinical Practice GuidelinesGeorge D. Demetri, John Zalcberg, Robert S. Benjamin et al.|Journal of the National Comprehensive Cancer Network|2007Cited by 636
Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665Burton Eisenberg, Margaret von Mehren, Jonathan Harris et al.|Journal of Surgical Oncology|2008Cited by 419